Investigational Site Number: 7240001

Madrid 28046

5 studies enrolling now · 19 studies all time

What they study most

Breast Cancer, Chronic Kidney Diseases, Crohn's Disease, Heart Failure, Hidradenitis Suppurativa, Hypercholesterolaemia, Metastatic Neoplasm, Non-small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Plasma Cell Myeloma Refractory, Pleural Mesothelioma, Relapsing Multiple Sclerosis

Studies at this site

• The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease — Recruiting now
• Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa — Recruiting now
• A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. — Recruiting now
• A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease — Recruiting now
• A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma — Recruiting now
• Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus — Running, not enrolling
• Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer — Stopped early
• Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC — Stopped early
• Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis — Completed
• A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) — Stopped early
• Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer — Stopped early
• Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis — Completed
• Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer — Stopped early
• Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) — Completed
• Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies — Stopped early
• A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD) — Completed
• Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk — Stopped early
• Effect of Efpeglenatide on Cardiovascular Outcomes — Stopped early
• An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia — Completed